Condition: Resistant Hypertension

This is a randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study to evaluate the efficacy and safety of drug CIN-107 compared to placebo in patients with treatment-resistant hypertension (rHTN). The study will assess three oral doses of CIN-107 versus placebo.

Location(s): Jacksonville (Headquarters)

Condition: Resistant Hypertension

PRECISION: The study is to evaluate the blood pressure lowering effect of aprocitentan when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure (hypertension), and to show that blood pressure reduction is kept for long period of time.

Location(s): St. Augustine

Condition: Resistant Hypertension